ATE226444T1 - Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten - Google Patents
Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheitenInfo
- Publication number
- ATE226444T1 ATE226444T1 AT99912439T AT99912439T ATE226444T1 AT E226444 T1 ATE226444 T1 AT E226444T1 AT 99912439 T AT99912439 T AT 99912439T AT 99912439 T AT99912439 T AT 99912439T AT E226444 T1 ATE226444 T1 AT E226444T1
- Authority
- AT
- Austria
- Prior art keywords
- retinal
- retinopathies
- fgf
- cells
- retinopathy
- Prior art date
Links
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 title abstract 3
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 title abstract 3
- 210000001116 retinal neuron Anatomy 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 230000016273 neuron death Effects 0.000 title 1
- 206010038923 Retinopathy Diseases 0.000 abstract 7
- 201000007737 Retinal degeneration Diseases 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000004258 retinal degeneration Effects 0.000 abstract 3
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 abstract 2
- 206010011878 Deafness Diseases 0.000 abstract 2
- 230000010370 hearing loss Effects 0.000 abstract 2
- 231100000888 hearing loss Toxicity 0.000 abstract 2
- 208000016354 hearing loss disease Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010053227 AIDS retinopathy Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 abstract 1
- 208000033379 Chorioretinopathy Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 208000034656 Contusions Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 206010073286 Pathologic myopia Diseases 0.000 abstract 1
- 206010036105 Polyneuropathy Diseases 0.000 abstract 1
- 208000005587 Refsum Disease Diseases 0.000 abstract 1
- 208000002367 Retinal Perforations Diseases 0.000 abstract 1
- 206010038848 Retinal detachment Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 208000027073 Stargardt disease Diseases 0.000 abstract 1
- 208000014769 Usher Syndromes Diseases 0.000 abstract 1
- 206010058990 Venous occlusion Diseases 0.000 abstract 1
- 208000036866 Vitreoretinopathy Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000021328 arterial occlusion Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000009519 contusion Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 208000001309 degenerative myopia Diseases 0.000 abstract 1
- 230000004340 degenerative myopia Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 108091008695 photoreceptors Proteins 0.000 abstract 1
- 239000000049 pigment Substances 0.000 abstract 1
- 230000007824 polyneuropathy Effects 0.000 abstract 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 230000004264 retinal detachment Effects 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 210000000242 supportive cell Anatomy 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4138398A | 1998-03-12 | 1998-03-12 | |
| US09/240,952 US6331523B1 (en) | 1998-03-12 | 1999-01-29 | Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5 |
| PCT/US1999/005375 WO1999045952A2 (en) | 1998-03-12 | 1999-03-10 | Method of preventing the death of retinal neurons and treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE226444T1 true ATE226444T1 (de) | 2002-11-15 |
Family
ID=26718088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99912439T ATE226444T1 (de) | 1998-03-12 | 1999-03-10 | Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1061943B1 (de) |
| JP (2) | JP3764047B2 (de) |
| AT (1) | ATE226444T1 (de) |
| AU (1) | AU754380B2 (de) |
| CA (1) | CA2322380C (de) |
| DE (1) | DE69903612T2 (de) |
| ES (1) | ES2186340T3 (de) |
| IL (1) | IL138033A0 (de) |
| WO (1) | WO1999045952A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1183051A2 (de) * | 1999-03-15 | 2002-03-06 | Chiron Corporation | Verwendung von rekombinanten expressionsvektoren zur behandlung oder vorbeugung von augenkrankheiten |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| WO2001025271A2 (en) * | 1999-10-02 | 2001-04-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| DE602004030103D1 (de) * | 2003-04-18 | 2010-12-30 | Advanced Medicine Res Inst | Mittel zur behanldung von krankheiten zur aufbringung auf das auge |
| JP2008064459A (ja) * | 2004-12-24 | 2008-03-21 | Univ Kurume | 色素上皮由来因子の定量法 |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| US8124093B2 (en) | 2008-07-16 | 2012-02-28 | Institute For Research In Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
| TWI702955B (zh) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ） |
| JP6628252B2 (ja) * | 2014-02-28 | 2020-01-08 | 国立大学法人京都大学 | 虚血性眼疾患の処置用の医薬組成物 |
| ES3042252T3 (en) | 2014-03-17 | 2025-11-19 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
| CN114480502A (zh) | 2015-03-02 | 2022-05-13 | 阿德夫拉姆生物技术股份有限公司 | 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法 |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6284194A (en) * | 1993-03-12 | 1994-09-26 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5) |
| EP0776218A2 (de) * | 1994-03-15 | 1997-06-04 | Prizm Pharmaceuticals, Inc. | Heparin bindende wachstumfaktoren zur gentherapie und behandlung von vordere augenerkrankungen |
| US5629284A (en) * | 1995-07-24 | 1997-05-13 | Meiji Milk Products Co., Ltd. | Method for treating retinal diseases |
| IL129379A (en) * | 1996-10-16 | 2008-12-29 | Zymogenetics Inc | Fibroblast growth factor homologues |
-
1999
- 1999-03-10 IL IL13803399A patent/IL138033A0/xx active IP Right Grant
- 1999-03-10 EP EP99912439A patent/EP1061943B1/de not_active Expired - Lifetime
- 1999-03-10 CA CA002322380A patent/CA2322380C/en not_active Expired - Lifetime
- 1999-03-10 WO PCT/US1999/005375 patent/WO1999045952A2/en not_active Ceased
- 1999-03-10 DE DE69903612T patent/DE69903612T2/de not_active Expired - Lifetime
- 1999-03-10 AT AT99912439T patent/ATE226444T1/de not_active IP Right Cessation
- 1999-03-10 ES ES99912439T patent/ES2186340T3/es not_active Expired - Lifetime
- 1999-03-10 AU AU30813/99A patent/AU754380B2/en not_active Expired
- 1999-03-10 JP JP2000535365A patent/JP3764047B2/ja not_active Expired - Lifetime
-
2005
- 2005-10-04 JP JP2005290896A patent/JP2006089489A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2322380C (en) | 2008-10-14 |
| EP1061943A1 (de) | 2000-12-27 |
| EP1061943B1 (de) | 2002-10-23 |
| ES2186340T3 (es) | 2003-05-01 |
| JP2006089489A (ja) | 2006-04-06 |
| WO1999045952A2 (en) | 1999-09-16 |
| CA2322380A1 (en) | 1999-09-16 |
| JP3764047B2 (ja) | 2006-04-05 |
| AU3081399A (en) | 1999-09-27 |
| DE69903612T2 (de) | 2003-07-10 |
| DE69903612D1 (de) | 2002-11-28 |
| IL138033A0 (en) | 2001-10-31 |
| JP2002526381A (ja) | 2002-08-20 |
| WO1999045952A3 (en) | 2000-11-23 |
| AU754380B2 (en) | 2002-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001009327A3 (en) | Method of preventing the injury or death of retinal cells and treating ocular diseases | |
| ATE226444T1 (de) | Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten | |
| NO982275D0 (no) | FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF) | |
| Valiente-Soriano et al. | BDNF rescues RGCs but not intrinsically photosensitive RGCs in ocular hypertensive albino rat retinas | |
| Guillery | Neural abnormalities of albinos | |
| Drucker et al. | Pathogenesis of post-traumatic sympathetic dystrophy | |
| Tsutsumi-Miyahara et al. | The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation | |
| Jirsova et al. | Cold jet: a method to obtain pure Schwann cell cultures without the need for cytotoxic, apoptosis-inducing drug treatment | |
| JP2004262947A (ja) | 網膜の色素沈着された上皮由来の神経栄養性因子 | |
| WO2000053760A3 (en) | Method of preventing the death of retinal neurons and treating ocular diseases | |
| Abe et al. | Lens epithelial changes and mutated gene expression in patients with myotonic dystrophy | |
| ITRM20100100A1 (it) | Composizione farmaceutica a base di glicirrizina e polimero eg56 per la preparazione di prodotti ad azione flogolitica. | |
| EP0083261B1 (de) | Therapeutische Zusammensetzung für die Behandlung von Schwierigkeiten des Anpassungsvermögens des Auges | |
| Copello et al. | Ozone therapy in patients with retinitis pigmentosa | |
| EP1059931B1 (de) | Verwendung von cd137 zur förderung der proliferation peripherer monocyten | |
| JPS6284025A (ja) | 繊維芽細胞増殖促進作用を有する胎盤由来蛋白加水分解物 | |
| Bernhard et al. | Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient | |
| Travers et al. | A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis | |
| Møller et al. | Early treatment of granular dystrophy (Groenouw type I) | |
| Srinivas et al. | Haridra (curcuma longa) and its effect on abhisayanda (conjunctivitis) | |
| EP1021461A1 (de) | Verwendung von blockern neuronaler und lymphozytärer kaliumkanäle zur behandlung von neurologischen krankheiten des immunsystems | |
| Saif et al. | CMV Retinitis | |
| Rotman et al. | Two asymptomatic plaques on the chest of a young woman | |
| RU2167667C1 (ru) | Гомеопатическое средство для рассасывания помутнений роговицы | |
| DE664816C (de) | Hilfsmittel fuer Beuchlaugen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REZ | Deleted due to withdrawal |